HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
14.21
+0.01 (0.07%)
Jan 21, 2025, 4:00 PM EST - Market closed
HUTCHMED (China) Employees
HUTCHMED (China) had 1,988 employees as of December 31, 2023. The number of employees decreased by 37 or -1.83% compared to the previous year.
Employees
1,988
Change (1Y)
-37
Growth (1Y)
-1.83%
Revenue / Employee
$307,246
Profits / Employee
-$21,112
Market Cap
2.39B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
HCM News
- 8 days ago - HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewsWire
- 19 days ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 20 days ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewsWire
- 20 days ago - Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales - Reuters
- 20 days ago - HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - GlobeNewsWire
- 5 weeks ago - HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - GlobeNewsWire
- 7 weeks ago - Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - PRNewsWire